• Profile
Close

Ultra-hypofractionated vs conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomized, non-inferiority, phase 3 trial

The Lancet Aug 07, 2019

Widmark A, Gunnlaugsson A, Beckman L, et al. - Via the open-label, randomized, Scandinavian HYPO-RT-PC phase 3 non-inferiority trial conducted in 12 centers in Sweden and Denmark with 1,200 men up to 75 years of age with intermediate-to-high-risk prostate cancer and a WHO performance status between 0 and 2, researchers intended to exhibit non-inferiority of ultra-hypofractionation vs conventional fractionation. In the ultra-hypofractionation group at the end of radiotherapy, weak evidence of a higher frequency of acute physician-reported Radiation Therapy Oncology Group (RTOG) grade 2 or worse urinary toxicity was noted. Among the two treatment groups at any point following radiotherapy, no notable variations in grade 2 or worse urinary or bowel late toxicity were seen, other than an increase in urinary toxicity in the ultra-hypofractionation group vs the conventional fractionation group at 1-year follow-up. No variations among groups in frequencies at 5 years of RTOG grade 2 or worse urinary toxicity and bowel toxicity could be ascertained. In conclusion, for intermediate-to-high risk prostate cancer relative to failure-free survival, ultra-hypofractionated radiotherapy was non-inferior to conventionally fractionated radiotherapy. With ultra-hypofractionation, early side-effects were more distinct vs conventional fractionation; late toxicity was comparable in both treatment groups. Moreover, for radiotherapy of prostate cancer, the results confirmed the use of ultra-hypofractionation.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay